Lyell Immunopharma (LYEL) vs MacroGenics (MGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
MacroGenics (MGNX) has outperformed Lyell Immunopharma (LYEL) over the past year, gaining 97.0% versus a loss of 50.8%. Over five years, MGNX leads with a -83.0% price change compared with -97.1% for LYEL. MacroGenics is the larger company by market cap ($207.0 million vs $199.0 million), about 1.0 times the size.
MacroGenics converts more of its revenue into profit, with a net margin of -49.9% versus -762355.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LYEL | MGNX |
|---|---|---|
| Share price | $8.12 | $3.25 |
| Market cap | $198.98M | $207.03M |
| 1-day change | -0.85% | -3.56% |
| YTD return | -73.62% | +101.86% |
| 1-year return | -50.79% | +96.97% |
| 5-year return | -97.06% | -82.99% |
| EPS (TTM) | $-12.86 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $36.00K | $149.50M |
| Revenue growth (YoY) | -40.98% | -0.31% |
| Net income (latest FY) | $-274.45M | $-74.62M |
| Gross margin | — | 100.00% |
| Operating margin | -748344.44% | -48.72% |
| Net margin | -762355.56% | -49.91% |
| 52-week high | $45.00 | $5.08 |
| 52-week low | $7.20 | $1.29 |
| Distance from 52-week high | -81.96% | -36.02% |
| Analyst consensus | none | none |
| Avg. price target upside | +366.50% | +146.15% |
| Average volume | 152.61K | 583.65K |
| Shares outstanding | 24.51M | 63.70M |
| Employees | 161 | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed LYEL by 147.8 percentage points over the past year.
- MacroGenics is more profitable, keeping -49.9 cents of every revenue dollar as net income versus -762355.6 cents for Lyell Immunopharma.
- MacroGenics grew revenue faster in its latest fiscal year (-0.31% vs -40.98%).
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
LYEL vs MGNX FAQ
Which is bigger, Lyell Immunopharma or MacroGenics?
MacroGenics (MGNX) is larger, with a market capitalization of $207.03M compared with $198.98M for Lyell Immunopharma (LYEL).
Which stock has performed better over the past year, LYEL or MGNX?
MGNX returned +96.97% over the past 12 months, compared with -50.79% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Lyell Immunopharma and MacroGenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.